. 2021 Jul 1;113(7):893-899.

doi: 10.1093/jnci/djaa203.

Performance of Breast Cancer Polygenic Risk Scores in 760 Female CHEK2 Germline Mutation Carriers

Julika Borde¹, Corinna Ernst¹, Barbara Wappenschmidt¹, Dieter Niederacher², Konstantin Weber-Lassalle¹, Gunnar Schmidt³, Jan Hauke¹, Anne S Quante⁴, Nana Weber-Lassalle¹, Judit Horváth⁵, Esther Pohl-Rescigno¹, Norbert Arnold⁶, Andreas Rump⁷, Andrea Gehrig⁸, Julia Hentschel⁹, Ulrike Faust¹⁰, Véronique Dutrannoy¹¹, Alfons Meindl¹², Maria Kuzyakova¹³, Shan Wang-Gohrke¹⁴, Bernhard H F Weber^{15

16}, Christian Sutter¹⁷, Alexander E Volk¹⁸, Olga Giannakopoulou^{19

20}, Andrew Lee²¹, Christoph Engel²², Marjanka K Schmidt²³, Antonis C Antoniou²¹, Rita K Schmutzler¹, Karoline Kuchenbaecker^{19

20}, Eric Hahnen¹

Affiliations

¹ Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
² Department of Gynecology and Obstetrics, University Hospital Duesseldorf, Heinrich-Heine University Duesseldorf, Duesseldorf, Germany.
³ Institute of Human Genetics, Hannover Medical School, Hannover, Germany.
⁴ Department of Gynecology and Obstetrics, Technical University Munich, University Hospital Rechts der Isar, Munich, Germany.
⁵ Institute for Human Genetics, University Hospital Muenster, Muenster, Germany.
⁶ Institute of Clinical Molecular Biology, Department of Gynaecology and Obstetrics, University Hospital of Schleswig-Holstein, Campus Kiel, Christian-Albrechts University Kiel, Kiel, Germany.
⁷ Institute for Clinical Genetics, Technische Universitaet Dresden, Dresden, Germany.
⁸ Institute of Human Genetics, Julius-Maximilians-Universität Würzburg, Würzburg, Germany.
⁹ Institute of Human Genetics, University of Leipzig Hospitals and Clinics, Leipzig, Germany.
¹⁰ Institute of Medical Genetics and Applied Genomics, University Hospital Tuebingen, Tuebingen, Germany.
¹¹ Institute of Medical and Human Genetics, Charité Universitätsmedizin Berlin, Berlin, Germany.
¹² Department of Gynecology and Obstetrics, Ludwig-Maximilians-University Munich, University Hospital Munich, Munich, Germany.
¹³ Institute of Human Genetics, University Medical Center, Georg August University, Goettingen, Germany.
¹⁴ Department of Gynaecology and Obstetrics, University Hospital Ulm, Ulm, Germany.
¹⁵ Institute of Human Genetics, University of Regensburg, Regensburg, Germany.
¹⁶ Institute of Clinical Human Genetics, University Hospital Regensburg, Regensburg, Germany.
¹⁷ Institute of Human Genetics, University of Heidelberg, Heidelberg, Germany.
¹⁸ Institute of Human Genetics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
¹⁹ Division of Psychiatry, University College London, London, UK.
²⁰ UCL Genetics Institute, University College London, London, UK.
²¹ Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, UK.
²² Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany.
²³ Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.

PMID: 33372680
PMCID: PMC8246885
DOI: 10.1093/jnci/djaa203

Performance of Breast Cancer Polygenic Risk Scores in 760 Female CHEK2 Germline Mutation Carriers

Julika Borde et al. J Natl Cancer Inst. 2021.

. 2021 Jul 1;113(7):893-899.

doi: 10.1093/jnci/djaa203.

Authors

Affiliations

¹ Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
² Department of Gynecology and Obstetrics, University Hospital Duesseldorf, Heinrich-Heine University Duesseldorf, Duesseldorf, Germany.
³ Institute of Human Genetics, Hannover Medical School, Hannover, Germany.
⁴ Department of Gynecology and Obstetrics, Technical University Munich, University Hospital Rechts der Isar, Munich, Germany.
⁵ Institute for Human Genetics, University Hospital Muenster, Muenster, Germany.
⁶ Institute of Clinical Molecular Biology, Department of Gynaecology and Obstetrics, University Hospital of Schleswig-Holstein, Campus Kiel, Christian-Albrechts University Kiel, Kiel, Germany.
⁷ Institute for Clinical Genetics, Technische Universitaet Dresden, Dresden, Germany.
⁸ Institute of Human Genetics, Julius-Maximilians-Universität Würzburg, Würzburg, Germany.
⁹ Institute of Human Genetics, University of Leipzig Hospitals and Clinics, Leipzig, Germany.
¹⁰ Institute of Medical Genetics and Applied Genomics, University Hospital Tuebingen, Tuebingen, Germany.
¹¹ Institute of Medical and Human Genetics, Charité Universitätsmedizin Berlin, Berlin, Germany.
¹² Department of Gynecology and Obstetrics, Ludwig-Maximilians-University Munich, University Hospital Munich, Munich, Germany.
¹³ Institute of Human Genetics, University Medical Center, Georg August University, Goettingen, Germany.
¹⁴ Department of Gynaecology and Obstetrics, University Hospital Ulm, Ulm, Germany.
¹⁵ Institute of Human Genetics, University of Regensburg, Regensburg, Germany.
¹⁶ Institute of Clinical Human Genetics, University Hospital Regensburg, Regensburg, Germany.
¹⁷ Institute of Human Genetics, University of Heidelberg, Heidelberg, Germany.
¹⁸ Institute of Human Genetics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
¹⁹ Division of Psychiatry, University College London, London, UK.
²⁰ UCL Genetics Institute, University College London, London, UK.
²¹ Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, UK.
²² Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany.
²³ Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.

PMID: 33372680
PMCID: PMC8246885
DOI: 10.1093/jnci/djaa203

Abstract

Background: Genome-wide association studies suggest that the combined effects of breast cancer (BC)-associated single nucleotide polymorphisms (SNPs) can improve BC risk stratification using polygenic risk scores (PRSs). The performance of PRSs in genome-wide association studies-independent clinical cohorts is poorly studied in individuals carrying mutations in moderately penetrant BC predisposition genes such as CHEK2.

Methods: A total of 760 female CHEK2 mutation carriers were included; 561 women were affected with BC, of whom 74 developed metachronous contralateral BC (mCBC). For PRS calculations, 2 SNP sets covering 77 (SNP set 1, developed for BC risk stratification in women unselected for their BRCA1/2 germline mutation status) and 88 (SNP set 2, developed for BC risk stratification in female BRCA1/2 mutation carriers) BC-associated SNPs were used. All statistical tests were 2-sided.

Results: Both SNP sets provided concordant PRS results at the individual level (r = 0.91, P < 2.20 × 10-16). Weighted cohort Cox regression analyses revealed statistically significant associations of PRSs with the risk for first BC. For SNP set 1, a hazard ratio of 1.71 per SD of the PRS was observed (95% confidence interval = 1.36 to 2.15, P = 3.87 × 10-6). PRSs identify a subgroup of CHEK2 mutation carriers with a predicted lifetime risk for first BC that exceeds the surveillance thresholds defined by international guidelines. Association of PRS with mCBC was examined via Cox regression analysis (SNP set 1 hazard ratio = 1.23, 95% confidence interval = 0.86 to 1.78, P = .26).

Conclusions: PRSs may be used to personalize risk-adapted preventive measures for women with CHEK2 mutations. Larger studies are required to assess the role of PRSs in mCBC predisposition.

PubMed Disclaimer

Figures

**Figure 1.**
Empirical distributions of the polygenic risk score (PRS) for single nucleotide polymorphism (SNP) set 1 (A) and SNP set 2 (B) in the overall cohort of 760 *CHEK2* mutation carriers. Values of theoretically expected mean $\bar{PRS}$ are indicated with vertical lines. (C) Standardized PRS values per individual for SNP set 1 and SNP set 2.

**Figure 2.**
Predicted cumulative breast cancer risks by percentile of the polygenic risk scores in *CHEK2* mutation carriers.

See this image and copyright information in PMC

References

1. Bleyer A, Welch HG.. Effect of three decades of screening mammography on breast-cancer incidence. N Engl J Med. 2012;367(21):1998–2005. - PubMed
1. Cuzick J, Sestak I, Bonanni B, et al. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet. 2013;381(9880):1827–1834. - PMC - PubMed
1. Howell A, Astley S, Warwick J, et al. Prevention of breast cancer in the context of a national breast screening programme. J Intern Med. 2012;271(4):321–330. - PubMed
1. Pashayan N, Duffy SW, Chowdhury S, et al. Polygenic susceptibility to prostate and breast cancer: implications for personalised screening. Br J Cancer. 2011;104(10):1656–1663. - PMC - PubMed
1. Burton H, Chowdhury S, Dent T, et al. Public health implications from COGS and potential for risk stratification and screening. Nat Genet. 2013;45(4):349–351. - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

Grants and funding

20861/CRUK_/Cancer Research UK/United Kingdom

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Performance of Breast Cancer Polygenic Risk Scores in 760 Female CHEK2 Germline Mutation Carriers

Affiliations

Performance of Breast Cancer Polygenic Risk Scores in 760 Female CHEK2 Germline Mutation Carriers

Authors

Affiliations

Abstract

Figures

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous